Human prothymosin alpha: amino acid sequence and immunologic properties.
Prothymosin alpha has been purified from human thymus and its amino acid sequence determined, except for a 15 amino acid segment including 10 glutamyl residues near the middle of the molecule. Like prothymosin alpha from rat thymus [A. A. Haritos, R. Blacher, S. Stein, J. Caldarella, and B. L. Horecker (1985) Proc. Natl. Acad. Sci. USA 82, 343-346], human prothymosin contains the thymosin alpha 1 sequence at its NH2-terminus. It contains a total of 109-110 residues compared to 111-112 for rat prothymosin alpha, with deletions corresponding to positions Gln39 and Lys108 of the rat polypeptide. Human prothymosin alpha also differs from rat prothymosin alpha at positions corresponding to residues 87, 92, and 102 of the latter, with substitutions of alanine for proline, alanine for valine, and aspartic acid for glutamic acid, respectively. Human prothymosin is significantly less active than rat prothymosin in protecting mice against infection with Candida albicans and in stimulating release in vivo of migration inhibitory factor. Thus, the differences in amino acid sequences, present mainly the COOH-terminal half of the polypeptides, may determine species specificity in biological properties.
D000595:Amino Acid Sequence; D000818:Animals; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D008263:Macrophage Migration-Inhibitory Factors / Q000378:metabolism; D051379:Mice; D008806:Mice, Inbred AKR; D008809:Mice, Inbred C3H; D010449:Peptide Mapping; D011498:Protein Precursors / Q000494:pharmacology; D051381:Rats; D013045:Species Specificity; D013947:Thymosin / Q000031:analogs & derivatives* / Q000494:pharmacology
D008263:Macrophage Migration-Inhibitory Factors; D011498:Protein Precursors; C040782:prothymosin alpha; D013947:Thymosin